Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi-Regeneron Secures Two New Cancer Nods for Libtayo Amid Rising Competition

06/25/2021 | 05:44am EDT


© MT Newswires 2021
All news about SANOFI
07/30REGENERON PHARMACEUTICALS : Dupixent significantly improved itch and hives in pa..
AQ
07/30SANOFI : Credit Suisse keeps its Buy rating
MD
07/30PRESS RELEASE : TubeSolar AG: TubeSolar AG nominated for the German Sustainabili..
DJ
07/30SANOFI : Receives a Buy rating from JP Morgan
MD
07/30EMEA MORNING BRIEFING : Stocks Set to Fall After -2-
DJ
07/29AMGEN : Federal Circuit Emphasizes High Bar For Enablement Of Functional Claims
AQ
07/29Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - exe..
RE
07/29SANOFI : Online availability of Sanofi's half-year financial report for 2021
GL
07/29Tranche Update on Sanofi's Equity Buyback Plan announced on January 8, 2021.
CI
07/29GLOBAL MARKETS LIVE : Earnings reports please investors
More news
Financials
Sales 2021 37 364 M 44 340 M 44 340 M
Net income 2021 6 143 M 7 290 M 7 290 M
Net Debt 2021 7 053 M 8 370 M 8 370 M
P/E ratio 2021 17,7x
Yield 2021 3,79%
Capitalization 109 B 129 B 129 B
EV / Sales 2021 3,10x
EV / Sales 2022 2,87x
Nbr of Employees 99 412
Free-Float 88,4%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 86,88 €
Average target price 104,06 €
Spread / Average Target 19,8%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI10.39%129 167
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348